CARE is a brand-new public-private partnership uniting researchers from scholastic community, proving ground, Sshopping mall Medium Enterprises (SMEs), European Federation of Pharmaceutical Industries and Associations (EFPIA) member business and IMI Associated Partners. In total, it comprises 37 different partner organizations. Teacher Yves Lévy from VRI-Inserm is the scholastic organizer, Marnix Van Loock from the Janssen Pharmaceutical Company of Johnson & Johnson is the EFPIA task leader and Kumar Saikatendu from Takeda is the job co-leader. The job partners are 11 scholastic companies (KUL, GUF, AMU, UzL UU, EDI-IVI, UHAM, UEDIN, TiHo, JU, LUMC), 5 public research study organisations (Inserm, CHUV, CEA, HZI, SERMAS) and 7 SMEs (IT, EVF, EXSCI, NUVISAN, SCIFEON, ENYO, AIB), together with eleven EFPIA members (Janssen, Takeda, Pfizer, ABBV, BI, Merck KgA, BAG, Novartis, Astellas, Servier and AiCuris), and three IMI2 Associated Partners (BMGF, UNIVDUN, GHDDI). *
About Boehringer Ingelheim
About the IMI
This job has actually received funding from the Ingenious Medicines Effort 2 Joint Undertaking (JU) under grant contract No 101005077. The JU gets assistance from the European Union’s Horizon 2020 research study and advancement program, EFPIA, BILL & MELINDA GATES STRUCTURE, GLOBAL HEALTH DRUG DISCOVERY INSTITUTE, UNIVERSITY OF DUNDEE.
* Please click the following link the List of partners: http://www.boehringer-ingelheim.com/press-release/launch-care-consortium
< a href="https://financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/europes-largest-initiative-launches-to-accelerate-therapy-development-for-covid-19-and-future-coronavirus-threats" target =" _ blank" > Source